Prince Pharmaceutical Co (ROCO:6935) Total Operating Expense: NT$112 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6935 Prince Pharmaceutical Co Ltd ROCO:6935
60 GF Score
Price NT$30.30
GF Value NT$42.13
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Prince Pharmaceutical Co Total Operating Expense?

Prince Pharmaceutical Co ROCO:6935 +0.17% 60 Total Operating Expense is NT$112 Mil as of Dec. 2025. GuruFocus rates ROCO:6935 with a GF Score™ of 60/100 and a GF Value™ of NT$42.13 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Prince Pharmaceutical Co's Total Operating Expense for the six months ended in Dec. 2025 was NT$58 Mil. Prince Pharmaceutical Co's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$112 Mil.

Prince Pharmaceutical Co Total Operating Expense Related Terms

Prince Pharmaceutical Co Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Prince Pharmaceutical Co's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prince Pharmaceutical Co Total Operating Expense Chart

Prince Pharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 126.58 137.95 127.41 123.63 111.67

Prince Pharmaceutical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.43 63.06 60.57 54.02 57.65
ROCO:6935
60GF Score
Prince Pharmaceutical Co Ltd ROCO:6935
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prince Pharmaceutical Co Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$112 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of NT$112 Mil mean?
Prince Pharmaceutical Co (ROCO:6935) has a Total Operating Expense of NT$112 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Prince Pharmaceutical Co and its competitors.
Is Prince Pharmaceutical Co's Total Operating Expense too high?
Prince Pharmaceutical Co's current Total Operating Expense is NT$112 Mil. Overall, Prince Pharmaceutical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prince Pharmaceutical Co's Total Operating Expense compare to ZTS and UTHR?
Prince Pharmaceutical Co's Total Operating Expense of NT$112 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Prince Pharmaceutical Co and its competitors. Prince Pharmaceutical Co's current Total Operating Expense is NT$112 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prince Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Prince Pharmaceutical Co (ROCO:6935) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$42.13, compared to a current price of NT$30.30 — trading 28.1% below its estimated fair value. The current Total Operating Expense is NT$112 Mil. Prince Pharmaceutical Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Prince Pharmaceutical Co (ROCO:6935), the current Total Operating Expense is NT$112 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prince Pharmaceutical Co (ROCO:6935) Overvalued in 2026?

Based on GuruFocus' analysis, Prince Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$30.30 is trading 28.1% below its estimated GF Value™ of NT$42.13. GuruFocus considers Prince Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for ROCO:6935:

  • Total Operating Expense: NT$112 Mil
  • GF Value™: NT$42.13 vs. price of NT$30.30 (28.1% below fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6935 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prince Pharmaceutical Co Business Description

Address Number 168, Keyunnan Road, Huwei Town, Yunlin, TWN, 632
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe and other regions.
60GF Score

Get the complete analysis for ROCO:6935

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$30.30
Price
NT$42.13
GF Value